Literature DB >> 15320721

Recent developments in the design of mechanism-based and alternate substrate inhibitors of serine proteases.

Jiaying Zhong1, William C Groutas.   

Abstract

A wide range of human diseases are associated with the aberrant activity of mammalian, viral, bacterial or parasitic proteases. These include members of all four classes of proteases, namely, serine, cysteine, aspartic and metallo- proteases. The involvement of proteases in disease states has provided the impetus behind studies related to the design of potent and selective inhibitors and their use as either therapeutic agents and/or pharmacological probes to gain a better understanding of the pathophysiology of a particular disease. This review focuses on recent developments related to the design of mechanism-based and alternate substrate inhibitors of serine proteases of mammalian and non-mammalian origin. Numerous examples are cited that illustrate the fundamental principles and subtleties associated with the design of covalent and non-covalent inhibitors of these enzymes. This is an exciting and promising area of investigation that will undoubtedly continue unabated in the future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15320721     DOI: 10.2174/1568026043387971

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

1.  Synthesis and Pharmacological Evaluation of Indole Derivatives as Deaza Analogues of Potent Human Neutrophil Elastase Inhibitors.

Authors:  Letizia Crocetti; Igor A Schepetkin; Giovanna Ciciani; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn; Claudia Vergelli
Journal:  Drug Dev Res       Date:  2016-07-30       Impact factor: 4.360

2.  Discovery and Biological Evaluation of Potent and Selective N-Methylene Saccharin-Derived Inhibitors for Rhomboid Intramembrane Proteases.

Authors:  Parul Goel; Thorsten Jumpertz; David C Mikles; Anežka Tichá; Minh T N Nguyen; Steven Verhelst; Martin Hubalek; Darren C Johnson; Daniel A Bachovchin; Isabella Ogorek; Claus U Pietrzik; Kvido Strisovsky; Boris Schmidt; Sascha Weggen
Journal:  Biochemistry       Date:  2017-12-12       Impact factor: 3.162

Review 3.  Neutrophil elastase inhibitors.

Authors:  William C Groutas; Dengfeng Dou; Kevin R Alliston
Journal:  Expert Opin Ther Pat       Date:  2011-01-16       Impact factor: 6.674

4.  Serine protease inhibition by a silanediol peptidomimetic.

Authors:  Swapnil Singh; Scott McN Sieburth
Journal:  Org Lett       Date:  2012-08-16       Impact factor: 6.005

5.  Design, synthesis, and in vitro evaluation of potential West Nile virus protease inhibitors based on the 1-oxo-1,2,3,4-tetrahydroisoquinoline and 1-oxo-1,2-dihydroisoquinoline scaffolds.

Authors:  Dengfeng Dou; Prasanth Viwanathan; Yi Li; Guijia He; Kevin R Alliston; Gerald H Lushington; Joshua D Brown-Clay; R Padmanabhan; William C Groutas
Journal:  J Comb Chem       Date:  2010-09-30

6.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase.

Authors:  Letizia Crocetti; Igor A Schepetkin; Agostino Cilibrizzi; Alessia Graziano; Claudia Vergelli; Donatella Giomi; Andrei I Khlebnikov; Mark T Quinn; Maria Paola Giovannoni
Journal:  J Med Chem       Date:  2013-07-25       Impact factor: 7.446

8.  Novel and Modified Neutrophil Elastase Inhibitor Loaded in Topical Formulations for Psoriasis Management.

Authors:  Andreia Nunes; Joana Marto; Lídia Maria Gonçalves; Sandra Simões; Rita Félix; Andreia Ascenso; Francisca Lopes; Helena Margarida Ribeiro
Journal:  Pharmaceutics       Date:  2020-04-14       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.